{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', '1.2.', 'Schema', 'Study ALXN1210-MG-306 Schematic', 'Screening', 'Randomized-Controlled Period', 'Open-Label Extension Period', '(up to 4 weeks)', '(26 weeks)', '(up to 2 years)', 'Ravulizumab IV\u00b9 (N=80)', 'Meningococcal', 'vaccination required', 'Receiving standard of care2', 'for all patients prior', 'No previous treatment with a', 'to administration of', 'complement-inhibitor', 'study drug', 'Placebo IV(N=80)', '1 Ravulizumab dosage regimen:', 'LOADING DOSE (Day 1) =', '2400 mg for patients weighing 40 kg to < 60 kg', '2700 mg for patients weighing > 60 kg to < 100 kg', '3000 mg for patients weighing > 100 kg', 'MAINTENANCE DOSE (Day 15 and every 8 weeks [q8w] thereafter) =', '3000 mg for patients weighing > 40 kg to < 60 kg', '3300 mg for patients weighing > 60 kg to < 100 kg', '3600 mg for patients weighing > 100 kg', '2', 'Standard of care treatment to remain stable throughout the Randomized-Controlled Period', 'Abbreviations: IV = intravenous; N = number [of patients]', 'Page 19 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', '1.3.', 'Schedule of Activities', 'Table 1:', 'Schedule of Activities: Screening Through End of the Randomized-Controlled Period', 'Clinical', 'Period/Phase', 'Screening', 'Randomized-Controlled Period', 'Deterioration', 'Study Visit', '1', '2', '3', '4', '5', '6', '7', '8', '9/ET2', 'Study Day', 'D1', 'D8', 'D15', 'D29', 'D71', 'D85', 'D127', 'D183', 'Window (day)', '2', ' 2', ' 2', ' 2', ' 2', '2', '+2', 'Weeks', '-4 to -2 W', 'W1', 'W2', 'W4', 'W10', 'W12', 'W18', 'W26', 'Informed Consent', 'X', 'Assessment of Inclusion/', 'X', 'X', 'Exclusion Criteria', 'Medical History', 'X', 'MG History\u00b3', 'X', 'MGFA Clinical Classification4', 'X', 'X', 'Weight', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Height', 'X', 'HIV-(1 and 2) testing', 'X', 'Vital Signs & Pulse Oximetry5', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Physical Examination', 'X', 'X', 'X', 'Abbreviated Physical', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Examination6', 'Concomitant Medication', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Non-Drug Therapy', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'MG Therapy Status', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Hospitalization Status', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Adverse Event', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'MG-ADL4,7', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'QMG4,8', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'MG-QOL15r', 'X', 'X', 'X', 'X', 'X', 'X', 'Neuro-QOL Fatigue', 'X', 'X', 'X', 'X', 'X', 'X', 'EQ-5D-5L', 'X', 'X', 'X', 'X', 'X', 'X', 'MGC4,8', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'MGFA-PIS4', 'X', 'X', 'X', 'X', 'C-SSRS Baseline/Screening', 'X', 'Version9', 'C-SSRS Since Last Visit', 'X', 'X', 'Version', 'ECG', 'X', 'X', 'AChR Ab', 'X', 'X', 'X', 'X', 'Page 20 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}